Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 16/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196229 | 0.88 | SMN1; SMN2 (0.41) | CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL10196207 | 0.87 | PTPN1 (0.36) | SMN1; SMN2LTA4HEPHX2CTSD | |
| SCHEMBL10196215 | 0.87 | CTSD (0.35) | SMN1; SMN2LTA4HEPHX2CTSD | |
| SCHEMBL10195490 | 0.87 | SMN1; SMN2 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL13190205 | 0.87 | SMN1; SMN2 (0.37) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL19070658 | 0.85 | EPHX2 (0.34) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL10196227 | 0.84 | KMT2A (0.41) | CYP3A4SMN1; SMN2 | |
| SCHEMBL10195515 | 0.82 | LTA4H (0.44) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL10196232 | 0.81 | CTSD (0.35) | SMN1; SMN2LTA4HCTSD | |
| SCHEMBL19070979 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | disclosed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20120021912-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021912-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010102848-A1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021912-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | CYP1A2 67/4885CYP3A4 424/4885CYP2D6 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.